1A.I. Virtanen Institute For Molecular Sciences, Kuopio, Eastern Finland, Finland; 2Ark Therapeutics Ltd., Kuopio, Eastern Finland, Finland; 3Temple University, Philadelphia, PA, United States
Angiogenic growth factors are used to treat myocardial infarct by improving blood flow and therefore prevent left ventricular remodelling. In this study, we applied cine imaging to evaluate therapeutic effects of intramyocardial lentiviral delivery of promoter targeted shRNA that mediates epigenetic effects. A significant decrease in infarct size was found in shRNA treated mice from day 4 to day 14 after infarction compared to control group. The increased VEGF-A levels detected by using ELISA and histological findings support the MRI findings and suggest the method a potential way to decrease infarct size and may find clinical applications in the future.